Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model
Source abstract
Abstract
Cancer cell survival and proliferation are correlated with increased metabolic activity and consequent oxidative stress, driving metabolic shifts that interfere with the immune response to malignant cells. This is the case of high-energy-demanding angioimmunoblastic T cell lymphoma (AITL), a highly aggressive cancer with poor survival rates, where malignant CD4+ PD-1 high T cells show increased mitochondrial activity and Reactive oxygen species (ROS) accumulation. Here, we report that administration of ROS scavenging cerium oxide (CeO 2 ) nanoparticles in an AITL preclinical mouse model leads to their preferential accumulation in the spleen, where the CD4+ PD-1 high T cells driving malignancy were significantly reduced. This was accompanied by activation of previously exhausted cytotoxic CD8+ T cells, restoring their potent antitumor function. As a result, survival rates dramatically increase with no observed toxicity to healthy cells or tissues. Overall, it highlights the correlation between increased energy demand, increased mitochondrial mass, increased PD-1 expression, increased ROS production, and immune suppression and how this vicious loop can be stopped by scavenging ROS.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Université Côte d’Azur
Equipe labellisée Ligue Contre le Cancer
Vall d’Hebron Research Institute (VHIR), Passeig Vall d’Hebron 119-129, Barcelona 08035, Spain
Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, Barcelona 08193, Spain
Institució Catalana de Recerca I Estudis Avançats (ICREA)
Networking Research Centre for Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN)
Instituto de Salud Carlos III
CRCT, Université de Toulouse, Inserm, CNRS
Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse
INSERMU955; Unité hémopathies lymphoïdes, Hôpitaux Universitaires Henri Mondor, Assistance publique des Hôpitaux de Paris
Université Paris-Est Créteil; Institut Mondor de Recherche Biomédicale
département de pathologie
AP-HP, Groupe hospitalo-universitaire Chenevier Mondor
Service Unité Hémopathies Lymphoides
CIRI, Université de Lyon; INSERM U1111; ENS de Lyon; University Lyon1; CNRS UMR5308
Funding
Agence Nationale de la Recherche · Ligue Contre le Cancer · Cancerop?le PACA · Institut National Du Cancer · Minist?re de l'Enseignement sup?rieur et de la Recherche · EuroNanoMed III
References (81)
Show source-provided references
1. 10.1016/j.immuni.2015.09.00110.1016/j.immuni.2015.09.001 ↗
2. 10.3389/fimmu.2023.129634110.3389/fimmu.2023.1296341 ↗
3. 10.1080/21645515.2019.157189210.1080/21645515.2019.1571892 ↗
4. 10.3390/cancers1410239210.3390/cancers14102392 ↗
5. 10.1038/s41591-022-02103-810.1038/s41591-022-02103-8 ↗
6. 10.1016/j.immuni.2015.08.01710.1016/j.immuni.2015.08.017 ↗
7. 10.1038/ni.298510.1038/ni.2985 ↗
8. 10.1038/s41590-020-0725-210.1038/s41590-020-0725-2 ↗
9. 10.1038/s41590-020-0793-310.1038/s41590-020-0793-3 ↗
10. 10.1038/s41590-020-00834-910.1038/s41590-020-00834-9 ↗
11. 10.1085/jgp.8.6.51910.1085/jgp.8.6.519 ↗
12. 10.1016/S0021-9258(18)84944-410.1016/S0021-9258(18)84944-4 ↗
13. 10.3389/fonc.2021.74072010.3389/fonc.2021.740720 ↗
14. 10.3389/fimmu.2017.0033010.3389/fimmu.2017.00330 ↗
15. 10.1038/ncomms769210.1038/ncomms7692 ↗
16. 10.1007/s10048-006-0032-610.1007/s10048-006-0032-6 ↗
17. 10.1158/0008-5472.CAN-16-120410.1158/0008-5472.CAN-16-1204 ↗
18. 10.1016/j.cmet.2020.11.00710.1016/j.cmet.2020.11.007 ↗
19. 10.1038/s42255-020-0256-z10.1038/s42255-020-0256-z ↗
20. 10.1038/s41568-020-0273-y10.1038/s41568-020-0273-y ↗
21. 10.1016/j.nantod.2021.10126910.1016/j.nantod.2021.101269 ↗
22. 10.1049/mna2.7000310.1049/mna2.70003 ↗
23. 10.1016/j.inoche.2021.10876210.1016/j.inoche.2021.108762 ↗
24. 10.1080/10667857.2020.186357310.1080/10667857.2020.1863573 ↗
25. 10.1016/j.jics.2024.10135010.1016/j.jics.2024.101350 ↗
26. 10.1002/anie.20180230910.1002/anie.201802309 ↗
27. 10.3389/fimmu.2022.75017510.3389/fimmu.2022.750175 ↗
28. 10.1016/j.jtemb.2018.07.01110.1016/j.jtemb.2018.07.011 ↗
29. 10.1016/j.freeradbiomed.2011.06.00610.1016/j.freeradbiomed.2011.06.006 ↗
30. 10.1016/j.jtemb.2021.12674210.1016/j.jtemb.2021.126742 ↗
31. 10.1021/acsnano.2c0544710.1021/acsnano.2c05447 ↗
32. 10.1016/j.jhep.2015.10.02010.1016/j.jhep.2015.10.020 ↗
33. 10.1016/j.msec.2017.11.01410.1016/j.msec.2017.11.014 ↗
34. 10.1016/j.cej.2022.13862010.1016/j.cej.2022.138620 ↗
35. Dillon C. D. · Nanotechnology · 2011 · 3 · 451
36. 10.1002/smll.20190732210.1002/smll.201907322 ↗
37. 10.1002/hep.3113910.1002/hep.31139 ↗
38. 10.1016/j.msec.2019.11053310.1016/j.msec.2019.110533 ↗
39. 10.1158/1535-7163.MCT-13-095010.1158/1535-7163.MCT-13-0950 ↗
40. 10.1016/j.ceramint.2022.06.32210.1016/j.ceramint.2022.06.322 ↗
41. 10.1002/adhm.20230019110.1002/adhm.202300191 ↗
42. 10.2139/SSRN.450035410.2139/SSRN.4500354 ↗
43. 10.1038/s41375-020-0990-y10.1038/s41375-020-0990-y ↗
44. 10.1182/blood-2016-09-69254110.1182/blood-2016-09-692541 ↗
45. 10.1186/s13046-024-02952-w10.1186/s13046-024-02952-w ↗
46. 10.1038/s41420-024-02061-910.1038/s41420-024-02061-9 ↗
47. 10.1186/s13046-024-03179-510.1186/s13046-024-03179-5 ↗
48. 10.1016/j.ccell.2019.07.00810.1016/j.ccell.2019.07.008 ↗
49. 10.3390/antiox1203076510.3390/antiox12030765 ↗
50. 10.1016/S0965-9773(99)00027-610.1016/S0965-9773(99)00027-6 ↗
51. 10.1021/nn403542p10.1021/nn403542p ↗
52. 10.1016/j.matlet.2011.05.02210.1016/j.matlet.2011.05.022 ↗
53. 10.1063/1.37201610.1063/1.372016 ↗
54. 10.1016/j.apcatb.2006.07.01810.1016/j.apcatb.2006.07.018 ↗
55. 10.1021/acs.jpclett.8b0289210.1021/acs.jpclett.8b02892 ↗
56. 10.1016/0039-6028(74)90091-010.1016/0039-6028(74)90091-0 ↗
57. 10.1016/S0039-6028(98)00257-X10.1016/S0039-6028(98)00257-X ↗
58. 10.1021/nl052024f10.1021/nl052024f ↗
59. 10.1038/nnano.2012.20710.1038/nnano.2012.207 ↗
60. 10.1039/D0NR02379E10.1039/D0NR02379E ↗
61. 10.1021/acs.bioconjchem.6b0057510.1021/acs.bioconjchem.6b00575 ↗
62. 10.3390/vaccines1208082910.3390/vaccines12080829 ↗
63. 10.1016/j.molliq.2019.11183910.1016/j.molliq.2019.111839 ↗
64. 10.1038/nbt134010.1038/nbt1340 ↗
65. 10.1007/s12185-016-2159-z10.1007/s12185-016-2159-z ↗
66. Chen J. · Invest. Ophthalmol. Visual Sci. · 2005 · 46 · 186
67. 10.3389/fimmu.2017.0097010.3389/fimmu.2017.00970 ↗
68. 10.3109/17435390.2014.94809010.3109/17435390.2014.948090 ↗
69. 10.3390/nano1111299110.3390/nano11112991 ↗
70. 10.1093/toxsci/kfs06710.1093/toxsci/kfs067 ↗
71. 10.1038/nnano.2009.24210.1038/nnano.2009.242 ↗
72. 10.3390/catal702004510.3390/catal7020045 ↗
73. 10.1039/C9EN00222G10.1039/C9EN00222G ↗
74. 10.1021/acs.jpcc.6b0565010.1021/acs.jpcc.6b05650 ↗
75. 10.1039/D2NR03586C10.1039/D2NR03586C ↗
76. 10.1186/s40364-020-00228-x10.1186/s40364-020-00228-x ↗
77. 10.1016/1074-7613(94)90087-610.1016/1074-7613(94)90087-6 ↗
78. 10.1073/pnas.95.13.755610.1073/pnas.95.13.7556 ↗
79. 10.1038/3507412210.1038/35074122 ↗
80. 10.1186/s12943-021-01316-810.1186/s12943-021-01316-8 ↗
81. 10.1021/nn200126a10.1021/nn200126a ↗